




PLATFORM SPECIALTY
PRODUCTS CORPORATION

Agriphar Acquisition

August 2014

Platform to Acquire Agriphar

Today, Platform announced a definitive agreement to acquire Agriphar, a bolt-on in our Crop Protection vertical



Agriphar and CAS are very complementary in terms of product range and distribution capabilities. We expect synergies in excess of 25% of Agriphar's underlying EBITDA

Note: Market Sizes based on management estimates.

1. Asset-Lite only.

Agriphar is a Perfect Match to our Strategic Criteria for Acquisitions



Platform's Investment Criteria

- “Asset-Lite, High-Touch” Business Model that Drives Free Cash Flow
- Experienced Management Team with Track Record of Success
- Leading Positions in Niche Markets
- Diversified Revenue Base
- Available at a Reasonable Price that is Accretive to Intrinsic Value per Share

Agriphar – Business & Transaction Overview

Business Description

- Niche player in the Agrochemical industry with a focus on European end-markets
- Core portfolio of 10 key molecules with several additional under development
- Owned-distribution subsidiaries in France, Spain, Greece and Italy
- Best-in-class product registration capabilities
- In-house formulation capabilities with factory in Ougree, Belgium

Transaction Overview

Overview

- Total consideration value of €300 million.
- Expected to be accretive to Adjusted EPS in 2015 pre-synergies

Financials

- 2013 Net Sales of approximately €127 million
- Adjusted EBITDA margin above 20%
- Capital expenditures (excluding capitalized registration expenses) below 2% of sales
- Attractive return on capital
- Expect synergies in excess of 25% of underlying EBITDA

Sources of Funding

- Transaction expected to be funded through a combination of cash on hand and debt

Timing

- Expected to close in the Q4 2014
- Subject to customary closing conditions and regulatory approvals